MX2023007067A - Proteinas recombinantes de union a cd3 y su uso. - Google Patents
Proteinas recombinantes de union a cd3 y su uso.Info
- Publication number
- MX2023007067A MX2023007067A MX2023007067A MX2023007067A MX2023007067A MX 2023007067 A MX2023007067 A MX 2023007067A MX 2023007067 A MX2023007067 A MX 2023007067A MX 2023007067 A MX2023007067 A MX 2023007067A MX 2023007067 A MX2023007067 A MX 2023007067A
- Authority
- MX
- Mexico
- Prior art keywords
- binding proteins
- nucleic acids
- recombinant
- methods
- pharmaceutical compositions
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 5
- 108091008324 binding proteins Proteins 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000008102 Ankyrins Human genes 0.000 abstract 1
- 108010049777 Ankyrins Proteins 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con proteínas recombinantes de unión que comprenden un dominio de repetición de anquirina diseñado con especificidad de unión por el CD3. Además, la invención se relaciona con ácidos nucleicos que codifican tales proteínas de unión, composiciones farmacéuticas que comprenden tales proteínas de unión o ácidos nucleicos, y el uso de tales proteínas de unión, ácidos nucleicos o composiciones farmacéuticas en métodos de activación localizada de células T en la enfermedad y en métodos para tratar enfermedades, tales como enfermedades infecciosas o cáncer, en un mamífero, incluido un ser humano.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126356P | 2020-12-16 | 2020-12-16 | |
| EP20216705 | 2020-12-22 | ||
| US202163182394P | 2021-04-30 | 2021-04-30 | |
| PCT/EP2021/086331 WO2022129428A1 (en) | 2020-12-16 | 2021-12-16 | Recombinant cd3 binding proteins and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007067A true MX2023007067A (es) | 2023-08-09 |
Family
ID=79282877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007067A MX2023007067A (es) | 2020-12-16 | 2021-12-16 | Proteinas recombinantes de union a cd3 y su uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240052033A1 (es) |
| EP (1) | EP4263608A1 (es) |
| JP (1) | JP2023554379A (es) |
| KR (1) | KR20230120139A (es) |
| AU (1) | AU2021403658A1 (es) |
| CA (1) | CA3202296A1 (es) |
| IL (1) | IL303629A (es) |
| MX (1) | MX2023007067A (es) |
| WO (1) | WO2022129428A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12331090B2 (en) | 2020-05-14 | 2025-06-17 | Molecular Partners Ag | Multispecific proteins |
| US11834504B2 (en) | 2021-03-09 | 2023-12-05 | Molecular Partners Ag | DARPin based multi-specific t-cell engagers |
| KR20240122764A (ko) | 2021-12-14 | 2024-08-13 | 몰리큘라 파트너스 아게 | 이중 결합 특이성을 갖는 설계된 반복 도메인과 이의 용도 |
| CN121263440A (zh) | 2023-06-06 | 2026-01-02 | 分子合作伙伴股份公司 | 重组cd2结合蛋白及其用途 |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| IL276944B (en) | 2015-04-02 | 2022-07-01 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
| WO2020065349A2 (en) * | 2018-09-28 | 2020-04-02 | The Chancellor, Masters And Scholars Of The University Of Cambridge | Vaccines and methods |
| WO2020245175A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
| AU2020286600A1 (en) * | 2019-06-04 | 2021-12-23 | Molecular Partners Ag | Recombinant FAP binding proteins and their use |
-
2021
- 2021-12-16 JP JP2023536343A patent/JP2023554379A/ja active Pending
- 2021-12-16 MX MX2023007067A patent/MX2023007067A/es unknown
- 2021-12-16 CA CA3202296A patent/CA3202296A1/en active Pending
- 2021-12-16 US US18/267,608 patent/US20240052033A1/en active Pending
- 2021-12-16 KR KR1020237024124A patent/KR20230120139A/ko active Pending
- 2021-12-16 WO PCT/EP2021/086331 patent/WO2022129428A1/en not_active Ceased
- 2021-12-16 IL IL303629A patent/IL303629A/en unknown
- 2021-12-16 AU AU2021403658A patent/AU2021403658A1/en active Pending
- 2021-12-16 EP EP21839513.5A patent/EP4263608A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021403658A1 (en) | 2023-06-29 |
| US20240052033A1 (en) | 2024-02-15 |
| IL303629A (en) | 2023-08-01 |
| WO2022129428A1 (en) | 2022-06-23 |
| KR20230120139A (ko) | 2023-08-16 |
| EP4263608A1 (en) | 2023-10-25 |
| CA3202296A1 (en) | 2022-06-23 |
| JP2023554379A (ja) | 2023-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007067A (es) | Proteinas recombinantes de union a cd3 y su uso. | |
| MX2022007120A (es) | Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso. | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
| MX2021014601A (es) | Proteinas recombinantes de union a fap y su uso. | |
| MX2022014326A (es) | Proteinas multiespecificas. | |
| MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| SA517390092B1 (ar) | مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| MY156286A (en) | Human il-23 antigen binding proteins | |
| NZ754051A (en) | Novel antibodies and uses thereof | |
| EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
| BR112017016336A2 (pt) | proteínas de ligação icos agonistas? | |
| IL187321A (en) | Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments | |
| IN2014MN01781A (es) | ||
| CL2009001001A1 (es) | Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares. | |
| NZ603570A (en) | Biological materials related to her3 | |
| MY200710A (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| WO2021116470A3 (en) | Recombinant peptide-mhc complex binding proteins and their generation and use | |
| MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
| MX2023011978A (es) | Captadores de cd70 novedosos basados en darpin. |